利伐沙班与华法林对非瓣膜性心房颤动患者的临床疗效对比  

Comparison of clinical efficacy of rivaroxaban and warfarin in patients with nonvalvular atrial fibrillation

作　　者：尹晓姝[1] Yin Xiaoshu(Department of Cardiology,Ganzhou People's Hospital,Ganzhou,Jiangxi,341000,China)

机构地区：[1]赣州市人民医院心内科,江西赣州341000

出　　处：《当代医学》2020年第14期72-74,共3页Contemporary Medicine

摘　　要：目的探究非瓣膜性心房颤动患者应用利伐沙班与华法林治疗的临床疗效。方法选取2017年1月至2018年1月在本院就诊的非瓣膜性心房颤动患者96例,随机分为A组和B组,每组48例。A组应用利伐沙班治疗,B组运用华法林治疗,对比两组治疗前后的凝血指标和心肌损伤指标变化,比较两组国际标准化比值(INR)达标率、血栓栓塞发生率,另外对比两组的出血性事件发生率。结果治疗后,两组凝血酶原时间(PT)、部分活化凝血活酶时间均延长(P<0.05),D-二聚体(D-D)、N末端B型利钠肽前体(NT-proBNP)水平均下降(P<0.05),但两组比较差异无统计学意义;两组INR达标率、血栓栓塞发生率比较差异无统计学意义,A组出血率明显低于B组(P<0.05)。结论利伐沙班与华法林治疗非瓣膜性心房颤动对改善患者的凝血指标、减轻心肌损伤及预防血栓栓塞的作用相当,而利伐沙班出血性事件发生率更低。Objective To investigate the clinical efficacy of rivaroxaban and warfarin in patients with nonvalvular atrial fibrillation. Methods 96 patients with non-valvular atrial fibrillation who were treated in our hospital from January 2017 to January 2018 were randomly divided into group A and group B, with 48 cases in each group. Group A was treated with rivaroxaban and group B The warfarin treatment was used to compare the changes of coagulation index and myocardial injury index before and after the treatment in the two groups, the comparison of the internationally labeled ratio(INR)compliance rate, the incidence of thromboembolism, and the incidence of bleeding events in the two groups. Results After treatment, the prothrombin time(PT) and partially activated thromboplastin time were prolonged(P<0.05), D-dimer(DD) and N-terminal B-type natriuretic peptide precursor(NTproBNP) were decreased(P<0.05), but there was no significant difference between the two groups. There was no significant difference in the INR compliance rate and the incidence of thromboembolism in the two groups. The bleeding rate in group A was significantly lower than that in group B(P<0.05). Conclusion Rivaroxaban and warfarin for non-valvular atrial fibrillation have comparable effects on improving coagulation parameters, reducing myocardial injury and preventing thromboembolism in patients, while rivaroxaban has a lower incidence of bleeding events.

关 键 词：非瓣膜性心房颤动 利伐沙班 华法林 

分 类 号：R541.75[医药卫生—心血管疾病]